Janssen R&D is a worldwide leader in delivering innovative medicines for the treatment of an array of health concerns. In order to produce such medicines and achieve the ultimate goal of helping people live healthy lives, effective management of information assets must be in place.
The primary activities associated with the pharmaceutical industry include management of the product portfolio and development of new breakthrough products. Given the huge investment made in building and supporting processes to maintain data, it is vital to establish consistency of business critical data in these systems to create substantial strategic advantages via improved productivity and quality of core deliverables.
Master data managemeent improves such data exchange between business functions. Governance with clear data ownership is critical, including well defined terms with business rules. A session at this week’s MDM Summit, Nov. 8-10 in New York, describes the various challenges and workarounds in the journey of MDM implementation at Janssen R&D.
The pharma industry is known for frequent mergers and acquisitions. Along with these acquisitions and mergers, the processes and systems are also merged. However, the data sources remain in different formats. Here MDM can and should play a major role.
While the pharma industry is slowly and broadly adapting MDM into business processes, Janssen R&D remains one of the pioneers. This team faced significant challenges while implementing the framework. Starting with a multi-domain MDM approach, the team added a few skill centric teams along the way. The ultimate aim was to ensure the accurate data in one single format.
Today, the MDM hub contains master data for multiple vital domains and is being used as the authoritative source for that data. Moreover, this master data is being consumed and used by various functions at Janssen R&D to increase the efficiencies of the clinical trial business process.
The session will cover such points as:
- Establishing the initial implementation framework for governance
- Determining plan changes based on flux in data challenges
- Provisioning for additional governance roles-- Why were they created? How did it help?
Leading the session will be Patrick Genyn and Supriya Moghe. Glenn is a healthcare professional with more than 28 years of pharmaceutical Industry experience. He is senior director of data standards at Janssen R&D LLC.
Supriya Moghe is a senior manager with Tata Consultancy Services. Moghe has over 14 years in the space of R&D supporting major business functions such as biostatistics and programming, eCRF development and most recently providing support to manage a delivery for a global Drug Development Information Governance team focusing on Master Data Management.
Register or login for access to this item and much more
All Information Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access